Vanguard Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History
Bought
Maintained
Sold
Other funds holding AMLX
SVCM
Vanguard Capital Management's AMLX Position: Q3 2026 in Review
Vanguard Capital Management increased its Amylyx Pharmaceuticals (AMLX) stake by 20% in Q3 2026, buying an estimated $22.6M and bringing the position to 5,077,511 shares worth $148M. The position accounts for ﹤0.01% of the portfolio, ranked #1290.
Vanguard Capital Management first reported a position in AMLX in Q1 2026 and has held it in 3 quarters since. 230 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.
- Vanguard Capital Management held 5,077,511 shares of Amylyx Pharmaceuticals worth $148M as of Q3 2026.
- Vanguard Capital Management bought 853,287 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $22.6M.
- Amylyx Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1290 holding.
- Vanguard Capital Management first reported a position in Amylyx Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
- 230 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.